Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A new skin gel form of tamoxifen has been developed and tested on women with non-invasive breast cancer, reducing cancer cell growth while minimizing side effects. The gel application was found to be effective in reducing blood clot risk associated with oral tamoxifen, offering a safer treatment option.
A*STAR's Bioprocessing Technology Institute has partnered with Roche to develop new cancer treatments using novel antibodies that can directly target and destroy cancer cells. The partnership aims to improve cancer detection and treatment, offering a potential breakthrough in cancer therapy.
The foundation has granted over $3.3 million to support the research of 16 early-career investigators pursuing novel ideas in cancer research. The recipients will focus on developing new treatments and understanding the underlying mechanisms of various types of cancers.
Researchers isolated breast cancer cells from patients' blood and expanded them in the lab, identifying new mutations and drug susceptibility. The study found a promising drug, Ganetspib, effective in killing tumor cells with specific genetic mutations.
Researchers at Massachusetts General Hospital developed a microchip-based device to capture and culture circulating tumor cells (CTCs) for genetic analysis and drug testing. The study found that cultured CTCs accurately reflect a tumor's genetic mutation over time, revealing new mutations and potential drug targets.
Researchers at the University of Manchester discovered a new drug, AZD3965, effective in treating small cell lung cancer. The treatment approach exploits the change in energy production in tumours, targeting monocarboxylate transporters involved in lactate movement.
A drug candidate developed to treat sickle cell disease has been acquired by Baxter International, advancing its clinical development activities. Aes-103 significantly reduces patients' pain in Phase II clinical trials, offering a potential breakthrough treatment.
Researchers at Rockefeller University have identified a protein called TARBP2 that triggers breast cancer's spread by blocking other proteins linked to neurodegeneration. This finding suggests new cancer therapies targeting this 'master regulator' could be effective.
A study by UT Southwestern found a five-fold increase in cancer patients using MyChart from 2009 to 2015, with those over 60 making up the majority of frequent users. The technology's convenience and ease of use contribute to its widespread adoption among this demographic.
Researchers have uncovered mutations in a cell-signaling pathway that plays a role in forming tumors. These genetic changes may expand treatments for patients, as drugs targeting some of these pathways are already available or in clinical trials.
A study found that genetic mutations in liver cells drive tumor formation in iCCA, with mutant proteins impairing liver cell development and increasing the risk of metastasis. Researchers discovered a potential treatment option by targeting IDH1/2 mutations, opening a new line of investigation for biomarkers and life-saving decisions.
A new study published in PNAS found that metabolic processes are significantly increased during sleep deprivation, with 27 metabolites found at higher levels. This discovery could be crucial when looking at the best time of day to test for diseases such as cancer and heart disease.
A phase 3 study of everolimus failed to improve overall survival in patients with advanced hepatocellular carcinoma, a type of liver cancer. In contrast, sorafenib is the only systemic therapy shown to significantly improve overall survival.
The EORTC presents a European solution for effective cancer drug development through collaborative molecular screening platforms. These platforms enable efficient access to new therapeutic agents and adapt clinical research to individual patient needs.
Researchers at H. Lee Moffitt Cancer Center & Research Institute developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze biomarkers in blood and tissue, helping identify therapeutic targets for melanoma treatment. The study identified alterations in cell signaling pathways in drug-resistant cells.
Scientists have discovered where microtubules form inside the mitotic spindle and how their starting points are transported to opposite poles. This breakthrough provides a better understanding of cell division and paves the way for more effective cancer treatments.
A recent study published in Annals of Internal Medicine found that current standard medical guidelines for childhood cancer survivors can be reduced, saving large cost-savings and little reduction in overall quality of patient care. The study suggests that screenings can be safely done cost-effectively and improve the quantity of patie...
A study by Wake Forest Baptist Medical Center found that St. John's wort use was associated with 28% of potentially harmful combinations in analyzed data. The herbal supplement can reduce the effectiveness of various medications, leading to impaired treatment outcomes and increased risk of conditions like serotonin syndrome.
A 30-year follow-up study found no link between fertility drugs and breast, ovarian, and uterine cancers, except for extended use of clomiphene citrate. The study of 12,193 women treated for infertility showed a higher risk of invasive breast cancer with clomiphene use in 12 or more treatment cycles.
A new study found that HIV-infected people diagnosed with early-stage cancer are two to four times more likely to receive inadequate treatment. The research suggests that a lack of clinical trial data and guidelines on treating HIV patients with cancer may contribute to this disparity.
Adding cetuximab or bevacizumab to combination chemotherapy improves survival for patients with KRAS wild-type untreated colorectal cancer, with both treatments offering approximately 30-month overall survival. Genetic testing is crucial to determine the benefit of these treatments.
Researchers discover synthetic triterpenoids suppress colon cancer onset by impeding inflammation and increasing 15-hydroxyprostaglandin dehydrogenase gene expression. Oral administration in mice shows promise for chemoprevention, with potential to delay or halt colon cancer development.
Researchers have discovered a partnership between MYC and non-coding RNA PVT1 that fuels cancer cells. This finding could lead to the development of drugs targeting PVT1, potentially controlling major cancer genes like MYC.
Researchers developed a hydrogel that releases chemotherapy drugs in short bursts triggered by ultrasound, improving cancer treatment outcomes. The self-healing gel approach offers a more effective and minimally invasive method for delivering drugs at the right place and time.
Saint Louis University researchers have discovered a molecular pathway that causes painful chemotherapy side effects and found a potential way to block it. A drug already approved for treating multiple sclerosis may also alleviate chemotherapy-induced peripheral neuropathy (CIPN) without affecting the medication's anticancer properties.
Early exposure to ultraviolet radiation from indoor tanning increases the risk of basal cell carcinomas in young people. Researchers found that teens and young adults who use indoor tanning devices are more likely to develop BCC, especially on the torso.
Supercomputer simulations reveal that Ras protein clusters warp cell membranes, leading researchers to investigate the design of new anticancer drugs. The study uses coarse-grained molecular dynamics simulations to understand the dynamics of Ras proteins and their interaction with the membrane.
A new tool, COST (COmprehensive Score for financial Toxicity), measures a patient's risk for and ability to tolerate financial stress in cancer care. The study found that financial toxicity affects 30% of cancer survivors, with significant impact on workability and quality of life.
Researchers discovered a genetic partnership between KRAS and YAP1, enabling cancer cells to survive in the absence of KRAS. This 'escape mechanism' must be blocked alongside shutting down oncogene KRAS to kill tumor cells.
Researchers at St. Joseph's Hospital and Medical Center discovered a new treatment for ovarian cancer that improves response rates and prolongs time until cancer recurrence. Trebananib, a peptide-Fc fusion protein, targets angiogenesis by inhibiting angiopoietin 1 and 2 binding to the Tie2 receptor.
Researchers developed a vaccine that triggered the growth of immune cell nodules within pancreatic tumors, reprogramming these intractable cancers. The vaccine, GVAX, consists of irradiated tumor cells modified to recruit immune cells, and boosted activity of molecular mechanisms that inhibit cancer-fighting immune cells.
A study of over 56,000 patients with inflammatory bowel disease found no association between TNF inhibitor use and increased cancer risk. However, the authors emphasize the need for continued long-term follow-up to monitor potential risks.
Researchers are testing the safety and effectiveness of AG-120, a new drug designed for patients with IDH1 gene mutations, in a clinical trial at the Virginia G. Piper Cancer Center Clinical Trials. The study aims to improve treatment options for patients with solid tumors, including brain tumors and gallbladder bile duct cancer.
A meta-analysis of 43 studies found that sedentary behavior increases the risk of colon, endometrial, and lung cancers. The risk increases with sitting time, even among physically active individuals, suggesting a detrimental impact on cancer prevention.
Researchers discovered that switching off and then reactivating the Pax5 gene can reverse cancer in a common childhood leukemia model. Restoring its function enables normal blood cell development and cures the disease. The findings offer a promising new strategy for treating leukemia with fewer side effects.
Researchers at Georgetown University Medical Center found that combining tamoxifen with hydroxychloroquine reverses resistance to the breast cancer drug in mice. The study's findings provide a promising new treatment option for women with advanced estrogen receptor-positive breast cancer.
Researchers at Case Western Reserve University found that existing cancer treatment bortezomib increases levels of the vascular-protective gene KLF2, preventing blood clot formation. This discovery has potential implications for managing thrombosis in patients with predispositions to clot formation.
A class of leukemia drug has been found to stimulate immunity against multiple cancer types. Inhibiting the p110δ enzyme helps boost the body's immune system to kill tumor cells.
A new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments. The agents deliver two types of payloads directly to cancer cells, resulting in direct imaging or treatment.
Mayo Clinic researchers have identified a new form of cancer caused by a chromosomal chimera, characterized by a biphenotypic sinonasal sarcoma. The rare tumor typically begins in the nose and may require disfiguring surgery to treat.
Researchers found an association between decreased carbohydrate intake and reduced breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor. The study suggests that personalized diets based on molecular characteristics of primary tumors may be possible, but further research is needed.
Scientists have identified a new biomarker called Neuromedin U (NmU) that may help predict and overcome resistance to newer anti-cancer drugs for HER2 positive cancers. The discovery could lead to more effective treatment strategies and improved patient outcomes.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
A new therapy that combines chemotherapy with radiounclide treatment has shown promising results in slowing or stopping the progression of neuroendocrine cancer. In a study of 68 patients, the therapy resulted in stabilization or regression of the disease in 70% of cases, leading to improved patient survival rates.
Researchers have discovered that over-expression of Cripto-1 makes lung cancer cells resistant to erlotinib, a widely used targeted therapy. Blocking Cripto-1 signaling restored sensitivity to the drug in cell lines and animals, suggesting a potential reversal mechanism.
Recent Medicare data release reveals high payments to a few doctors, but experts caution that this does not necessarily indicate poor care. The data only shows the amount of care provided, not its appropriateness, and may be influenced by factors such as specialty and geography.
Healthcare experts examine potential cost savings in maternal mortality reduction, adolescent cancer treatment, and biosimilar medication use. Studies reveal the importance of long-term financing plans and access to follow-up care for improved outcomes.
Scientists at EPFL introduce a novel biosensor molecule that can quickly measure drug concentration in patients' systems using a digital camera. The method is simple, low-cost, and can be used by patients themselves.
Researchers found that early palliative support services significantly reduced depression and feelings of overwhelm among family caregivers, improving overall quality of life. The study suggests that timely intervention can better equip caregivers to cope with the demands of caring for patients with advanced cancer.
Researchers at Mayo Clinic have demonstrated a potential delivery vehicle for brain cancer chemotherapy drugs, enabling the transport of eight different molecules across the blood-brain barrier. The breakthrough method mimics a normal physiological process and could aid in evaluation of new drugs for brain cancer treatment.
Researchers develop new computational method to design novel protein nanostructures, including cage-like proteins with symmetrical architectures. These structures may be used to deliver cancer drugs directly to tumor cells, sparing healthy cells.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
A study found that approximately 25% of children with acute lymphocytic leukemia (ALL) are missing too many doses of essential maintenance medication, which minimizes the risk of relapse. Nonadherence triples relapse risk, with African Americans and Asians being more prone to non-adherence than non-Hispanic whites.
The DREAM project has successfully mined genomic data to predict breast cancer cell line responses to drugs, achieving 78% accuracy in identifying sensitive versus resistant cell lines. The study also identified molecular markers that can be tested against large collections of human samples.
A phase 1b immunotherapy trial combining nivolumab and ipilimumab has shown high one-year and two-year overall survival rates of 94% and 88%, respectively, in advanced melanoma patients. The treatment regimen has demonstrated long-lasting benefits for these patients.
Research confirms BRCA2 gene mutations increase lung cancer risk by 1.8 times in smokers and double the risk for some individuals. The study also identified associations with CHEK2 and TP63 genes, highlighting potential targets for early screening and treatment.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A preclinical study of Rice University's quadrapeutics technology found that it can detect and kill cancer cells instantly, without harming surrounding normal organs. The technology uses a combination of existing clinical treatments and mechanical events triggered by nano-explosions to target cancer cells.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A new trial found that giving chemotherapy immediately to men with newly diagnosed, hormone-sensitive prostate cancer can extend their survival by more than a year. The study showed significant benefits in both overall and high-extent disease populations.